Osteogenic protein-1 (bone morphogenic protein-7) combined with various adjuncts in the treatment of humeral diaphyseal nonunions.
A prospective study was conducted to determine the efficacy of using recombinant BMP-7 (rhOP-1) as an adjuvant in the treatment of diaphyseal humeral nonunions. Twenty-three consecutive patients with atrophic humeral diaphyseal nonunions were treated at seven separate institutions. All nonunions were fixed with either a compression plate or an intramedullary nail in conjunction with various bone grafting techniques. Recombinant OP-1 was delivered to the fracture site in a Type I collagen carrier at the time of fixation. All fractures went on to eventual union. There were no serious complications and no adverse reactions to the rhOP-I implant. Our study suggests that rhOP-1 may be a safe and effective adjuvant for the treatment of humeral diaphyseal nonunions.
NYU-HJD Department of Orthopaedic Surgery, Hospital for Joint Diseases New York, New York, USA.
Matthew R
MR
Bong
Edward L
EL
Capla
Kenneth A
KA
Egol
Anthony T
AT
Sorkin
Michael
M
Distefano
Rosemary
R
Buckle
Robert W
RW
Chandler
Kenneth J
KJ
Koval
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D001858:Bone Nails; D001860:Bone Plates; D003131:Combined Modality Therapy; D005260:Female; D005599:Fractures, Ununited / Q000601:surgery*; D006801:Humans; D006810:Humeral Fractures / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011446:Prospective Studies; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta